0.68

2.72% 0.018

Fractyl Health Inc (GUTS)

Overview News Price History Discussions Forecast

Fractyl Health Inc stock is traded at $0.68, with a volume of 740.48K. It is up +2.72% in the last 24 hours and down -15.00% over the past month. Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.

Previous Close:

$0.662

Open:

$0.677

24h Volume:

740.48K

Relative Volume:

0.41

Market Cap:

$108.24M

Revenue:

$3,000

Net Income/Loss:

$-108.00M

P/E Ratio:

-0.453

EPS:

-1.501

Net Cash Flow:

$-87.84M

1W Performance:

-2.80%

1M Performance:

-15.00%

6M Performance:

+62.52%

1Y Performance:

-30.43%

1-Day Range:

$0.6569

$0.70

1-Week Range:

$0.64

$0.73

52-Week Range:

$0.3772

$2.445

Fractyl Health Inc Stock (GUTS) Company Profile

Name

Fractyl Health Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

781-902-8800

Address

3 VAN DE GRAAFF DRIVE, BURLINGTON

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

GUTS's Discussions on Twitter

Compare GUTS vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GUTS Fractyl Health Inc	0.68	110.79M	3,000	-108.00M	-87.84M	-1.501
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-15-25	Initiated	H.C. Wainwright	Buy
Aug-28-25	Initiated	Ladenburg Thalmann	Buy
Feb-28-24	Initiated	Evercore ISI	Outperform
Feb-27-24	Initiated	BofA Securities	Buy
Feb-27-24	Initiated	Morgan Stanley	Overweight

View All

Fractyl Health Inc Stock (GUTS) Latest News

02:09 AM

Fractyl Health (NASDAQ:GUTS) Downgraded by Wall Street Zen to Sell - MarketBeat

02:09 AM

Aug 14, 2026

Fractyl Health (GUTS) seeks approval for 1-for-5 to 1-for-15 reverse stock split - Stock Titan

Aug 14, 2026

H.C. Wainwright Reiterates Top Pick on Fractyl Health - Investing.com

Aug 14, 2026

Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial - MarketBeat

Aug 14, 2026

Should I Buy GUTS (Fractyl Health, Inc. Common Stock) | AI Analysis, Technical & News Insights - Kavout | AI

Aug 14, 2026

Aug 13, 2026

Fractyl Health, Inc.Common Stock (Nasdaq:GUTS) Stock Quote - FinancialContent

Aug 13, 2026

Q3 EPS Estimates for Fractyl Health Raised by HC Wainwright - MarketBeat

Aug 13, 2026

Aug 12, 2026

Fractyl Health at Canaccord conference: betting on post-glp-1 care - Investing.com Nigeria

Aug 12, 2026

Analysts Set Expectations for Fractyl Health FY2028 Earnings - MarketBeat

Aug 12, 2026

Aug 11, 2026

Fractyl Health, Inc. Common Stock Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 11, 2026

Fractyl Says Revita Procedure Kept Off 80% of GLP-1 Weight Loss in One-Year Data - finance.biggo.com

Aug 11, 2026

BofA Securities Maintains Fractyl Health(GUTS.US) With Buy Rating, Maintains Target Price $2 - Moomoo

Aug 11, 2026

Earnings call transcript: Fractyl Health beats Q2 2026 EPS estimates By Investing.com - Investing.com UK

Aug 11, 2026